Oncology Clinical Trials - Current As Of January 2026

TUMOUR	TRIAL	Line	KEY POINTS - TRIAL/AGENT	PI	SC
Breast	INAVO	1st	A ph III study evaluating Inavolisib in combo with Phesgo vs placebo in combi with phesgo as maintenance therapy after 1st line induction tx in pts w PIK3CA mutated HER2 positive locally advanced or metastatic breast cancer	MW	JG
Breast	CAMBRIA-2	Adj	A Ph III, study to assess Camizestrant (AZD9833) vs Standard Endocrine Therapy for pts With ER+/HER2- Early Breast Cancer and an Intermediate-High/High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease	AM	RC
Breast	OLIO	Neoadj.	A ph II, randomised, non-comparative two-arm trial of neoadjuvant chemo plus either olaparib or olaparib + durvalumab in young, pre-menopausal women with HRD-enriched, HR-positive, HER2-negative early breast cancer	AM	RC
Breast	MONITOR HER2	N/A	Frequency of Cardiac Monitoring in Patients Treated with HER2-Directed Therapies for Breast Cancer	DD	JG
Breast	CECI830A12101	2nd	Ph I/II study of ECI830 as a single agent and in combination with ribociclib and endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and advanced solid tumors	MW	JG
Breast	DESTINY BREAST 15	2nd	Ph 3b, Multicenter, Global, Interventional, Open-label Study of T-DXd, an Anti-HER2-ADC, in Subjects who Have Unresectable and/or Metastatic HER2-low or HER2 IHC 0 Breast Cancer	MW	JG
Breast	OPERA-01	2nd +	Ph 3 study of OP-1250 monotherapy VS SOC for the tx of ER+, HER2- advanced or metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy	DD	RC
Breast	Ascent-05	1st	A Ph 3 study of adjuvant sacituzumab govitecan and pembrolizumab vs treatment of physician's choice in patients with TNBC who have residual invasive disease after surgery and neoadjuvant therapy	MW	JG
Breast	STML-ELA-0422	Adj	Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)	MW	JG
Breast	CLEE011O12001	Adj	A phase IIIb study to characterize the efficacy and safety of Adjuvant ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2− early breast cancer (Adjuvant WIDER)	MW	JG
Breast	OP1250-302 (Opera-02)	1st	A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant with Ribociclib Versus Letrozole with Ribociclib for the First-Line Treatment of ER+, HER2– Advanced Breast Cancer (OPERA-02)	AM	JG
Breast	MK2870-032	1st	A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer	MW	RC
All tumour types	KN-587	Any	Ph 3, Long term safety and efficacy in patients currently on treatment or followup from a Pembrolizumab trial	DL	KB
Biliary Tract	DESTINY-Biliary-01	1st	Ph 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig vs Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer	ZW	JP
Solid Tumours	HERTHENA	2nd +	A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects with Locally Advanced or Metastatic Solid Tumors	SF	SH
Solid Tumours	Genescreen	Any	GeneScreen 5-FU: DPYD Genotype-guided dose Personalisation for Fluoropyrimidine prescribing in Solid Organ Cancer Patients	ZW	MJ
Unknown primary	SUPER-ED	NA	Solving Unknown Primary cancER Earlier Diagnosis (SUPER-ED): A stepped wedge cluster randomised controlled trial implementing a Model of Care to support earlier diagnosis	ZW	KB
Pancreas	NEOFOL-R	1st	Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicenter Randomized, controlled trial	DL	MJ
Biliary Tract	BIL-PPP	2nd +	Phase II study of the combination of durvalumab (MEDI4736) (PDL1 inhibitor) and olaparib (PARP inhibitor) in advanced cholangiocarcinoma after initial chemotherapy and durvalumab (BIL-PPP)	DL	SH
GOJ	Destiny gastric 05	1st	A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-line Treatment in Participants with Unresectable, Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction (GEJ) Cancer (DESTINY-Gastric05)	DL	MJ
Gastric/GOJ	Lucerna	1st	A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive	ZW	KB
Colorectal	KANDLELIT-012	1st	A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)	ZW	JP
Pancreas	PemOla	Any	A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with mismatch repair deficiency or tumour mutation burden > 4 mutations/Mb	AS	MJ
Prostate	AMG 509	3rd	Ph I, AMG 509 in Subjects with Metastatic Castration-resistant Prostate Cancer	HH	LD

Oncology Clinical Trials - Current As Of January 2026

Prostate	MK5684-004	2nd +	Ph 3, Randomized, Open-label Study of MK-5684 vs Alternative Abiraterone Acetate or Enzalutamide in pts w mCRPC That Progressed On or After Prior Treatment with One Nextgeneration Hormonal Agent (NHA)	HH	SM
Prostate	GO44537	2nd +	Ph I, Open-Label, Multicenter, Dose-Escalation And Expansion Study Evaluating The Safety, Pharmacokinetics, And Activity Of RO7656594 In pts w Advanced Or Metastatic Prostate Cancer	EL	LD
Prostate	MEVPRO-1 C2321014	2nd +	A Ph 3, Randomized, Open-Label Study Of PF-06821497 (Mevrometostat) In Combo With Enzalutamide Compared With Enzalutamide Or Docetaxel In Participants With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate	HH	EQ
Prostate	20230005	2nd +	A Ph 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in pts w Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy	HH	SW
Prostate	CJSB462C12201	1st	A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive prostate cancer (mHSPC)	HH	HG
Endocrinology	I-FIRST	Any	A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients with RAIR Thyroid Cancer (I-FIRST study)	MM	LD
Prostate	AMG 20230239	1st	A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer	DP	SL
HNSCC	GS-US-699-7184	2nd +	A Phase 2 Platform Study of Novel Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma	MA	EQ
Neuro	LUMOS2	2ND	Phase 2, multi-centre, open-label, biomarker-directed, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma.	EA	SL

Breast | Gastrointestinal (GI) | Lung | Genitourinary (GU) | Gynaecology | Head & Neck | Skin | Neuro | PH 1

TUMOUR	TRIAL	Line	KEY POINTS - TRIAL/AGENT	PI	SC
NSCLC	OCEANiC	Adjuvant	Phase II, Open-label, Multi-centre Clinical Trial of Osimertinib With or Without Adjuvant Chemotherapy Guided by Tumour NGS Co-mutation Status and ctDNA Detection in Patients With Stage IIA-IIIA EGFR-Mutant NSCLC Following Complete Surgical Resection	SA	BN
NSCLC	eVOLVE lung 02	1st	Ph III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine Efficacy of Volrustomig (MEDI5752) + Chemo vs Pembrolizumab + chemo for First-Line Treatment of pts with mNSCLC	SA	BN
NSCLC	MK-2870-004	3rd	A Randomized, Open-label, Ph 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations	SA	BN
NSCLC	Tropion-10	1s	Ph III Study of Dato-DXd in Combo w AZD2936 or AZD2936 Monotherapy vs Pembro Monotherapy for First-line tx of Pts w Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations	SA	BN
NSCLC	Tropion-14	1st	Ph III Study of Osimertinib With or Without Dato-DXd as First-line Treatment in Participants w/ EGFR Mutation-positive, Locally Advanced or Metastatic NSCLC	SA	HS
Meso	eVOLVE meso	1st	Ph III, Randomized, Study of Volrustomig (MEDI5752) in Combo w Carboplatin plus Pemetrexed vs Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in pts with Unresectable Pleural Mesothelioma	SA	AF
SCLC	DeLLphi- 306	Adjuvant	A Phase 3, Randomized, double-blind, placebo-controlled, multicentre study of Tarlatamab Therapy in subjects with limited stage small cell lung cancer (LS-SCLC) who have not progressed following concurrent chemoradiation therapy.	SA	BN
SCLC	DeLLphi-309	2nd	A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with SCLC	SA	ZF
SCLC	Dellphi-312	1st	A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)	SA	AF
Endometrial	XPORT-EC-042	2nd +	Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma	KW	HT
Ovarian	IMGN853-0425	2nd +	A randomized Phase 2, open-label study of mirvetuximab soravtansine in patients with platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression testing 2 schedules of administration for dose optimization, with a separate cohort to determine starting dose in patients with moderate hepatic impairment	KW	ED
Gynaecological Neoplasms	IMGN151-1001	2nd +	A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRα antibody-drug conjugate) in Adult Patients with Recurrent Gynaecological Cancers	KW	DG
Ovarian	FLORENZA		A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Mirvetuximab Soravtansine in Subjects with Ovarian Cancer (FLORENZA)	KW	ED
Ovarian	Catalina-2	2nd +	A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6	GH	DS

Monash Health

Oncology Clinical Trials - Current As Of January 2026

Breast | Gastrointestinal (GI) | Lung | Genitourinary (GU) | Gynaecology | Head & Neck | Skin | Neuro | PH 1

TUMOUR	TRIAL	Line	KEY POINTS - TRIAL/AGENT	PI	SC
Solid Tumour	SR854A-001	2nd +	Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 inhibitor) Administered Orally as Monotherapy in Subjects with Advanced/Metastatic Solid Tumors	AB	LS
Solid Tumour	EOHC-1001-101	2nd+	Ph1, dose escalation of EO1001 (oral pan-ErbB inhibitor) in patients with Advanced solid tumours positive for EGFR, HER2 or HER4.	SF	PM
Solid Tumour	VT3989-001 - Vivace	2nd +	Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in pts with Locally Advanced or Metastatic Solid Tumors	AB	PM
Solid Tumour	CP-AU-007-01	2nd +	Ph 1 first in human dose escalation of AU-007 monoclonal antibody to IL2 in advanced solid tumours	SF	OC
Solid Tumour	MK-1084	2nd +	Ph 1, MK-1084 (KRAS G12C inhibitor) as monotherapy in advanced solid tumours or in combination with pembrolizumab (NSCLC)	EA	HA
Solid Tumour	AXA-042-FIH-01	2nd +	Ph1, A Phase 1a/1b, first-in-human, open-label, non-randomized, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy and in combination with checkpoint inhibitors in subjects with advanced solid tumours.	SF	HA
Solid Tumour	Genentech GO43860	2nd +	A Phase 1a/1b open label, multicentre, dose-escalation study to evaluate the safety, pharmacokinetics, and activity of RO7502175 as a single agent and in combination with atezolizumab in patients with locally advanced or metastatic solid tumours	SF	HA
Solid Tumour	HM-EZHI-101	2nd +	A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients With Advanced or Metastatic Solid Tumours	AB	KD
Solid Tumour	GS-US-570-6015	2nd +	Phase 1 study of GS-1811 as monotherapy and in combination with a checkpoint inhibitor in patients with advanced solid tumours	DD	PM
Solid Tumour	IOS-1002-201	2nd +	Ph 1a/1b, FIH, open-label, non-randomized, multicenter, dose-escalation and cohort expansion study to IOS-1002 administered alone and in combo with a PD-1 monoclonal antibody in advanced solid tumors	EA	LM
Solid Tumour	AWT020	2nd +	Ph 1/2, FIH, Open-label Study of Single-agent AWT020 in pts w Progressive Locally Advanced or Metastatic Cancer	SF	LS
Solid Tumour	DCSZ11-101	2nd +	Ph 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to DCSZ11 as a Monotherapy and in Combo in pts with Advanced or Metastatic Solid Tumors	DD	HA
Solid Tumour	BG-68501-101	2nd +	A Phase 1a/1b Study of BG-68501 a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors	DD	LS
Solid Tumour	BG-C9074-101	2nd +	Ph 1a/1b Study of BG-C9074, an ADC Targeting B7H4, as Monotherapy and in combo w/ Tislelizumab in pts With Advanced Solid Tumors	AB	OC
Solid Tumour	PMV-586-101	2nd +	A Ph 1/2 Open-label, Multicenter Study to Assess PC14586 in pts w/ Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation	AB	KD
Solid Tumour	PRT7732-01	2nd +	A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation	AB	LM
Solid Tumour	DM001001	2nd +	A Phase I, Multicenter, Open-label, FIH, Dose Escalation and Expansion Study of DM001 in Patients with Advanced Solid Tumors	SF	OC
Solid Tumour	YL211-INT-101-01	2nd +	A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients with Advanced Solid Tumors	SF	OC
Solid Tumour	BGB-53038-101	2nd +	A Ph 1a/1b Study to Investigate BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combo in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification	SF	HA
Solid Tumour	BG-C137-101	2nd +	A Phase 1a/b, Open-label, Multicenter Study to Investigate BG-C137, an Antibody-Drug Conjugate Targeting FGFR2b, in Patients With Advanced Solid Tumors	AB	LM
Solid Tumour	PAUF-I	2nd +	A FIH, Phase 1/2a, Multicentre, Open-label Study Evaluating PBP1510 in Patients with Advanced/Metastatic Pancreatic Cancer	AB	PM
Solid Tumour	BGB-58067-101	2nd +	A Ph 1a/b Study Investigating BGB-58067, an MTA-Cooperative PRMT5 Inhibitor in Patients With Advanced Solid Tumors	EA	LM
Solid Tumour	CP-IVX037	2nd +	A ph 1 study of intratumoral IVX037 as monotherapy or in combo w an immune checkpoint inhibitor in pts w advanced/metastatic solid tumors	SF	LM
Solid Tumour	BNT317	2nd +	Ph I, FIH, open-label, dose escalation study of BNT317 in pts w advanced solid tumors	SF	PM
Solid Tumour	CS2009-101	2nd +	Ph I, Dose-Escalation and Dose-Expansion Study to Evaluate CS2009, a tri-specific antibody targeting PD-1/VEGFA/CTLA-4, in Participants with Advanced Solid Tumors	SF	PM
Solid Tumour	BM230-01	2nd +	Ph I, Multicenter, Non-randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BM230 in Patients with Advanced Solid Tumors	EA	LS
Solid Tumour	SNV1521-101	2nd +	Ph I, open-label dose escalation and expansion study of SNV1521 in pts with advanced solid tumors	SF	LS
Solid Tumour	SNV4818-101	2nd +	Ph I, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in combo w other Anticancer Agents in pts with Advanced Solid Tumors.	SF	OC
Solid Tumour	MOMA-341-001	2nd +	A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants with Advanced or Metastatic Solid Tumors	EA	LM

Oncology Clinical Trials - Current As Of January 2026

Breast | Gastrointestinal (GI) | Lung | Genitourinary (GU) | Gynaecology | Head & Neck | Skin | Neuro | PH 1

Stream Contact Numbers

Breast – 0459 302 205
Gynaecological – 0491 299 561
GI – 0436 386 758
Lung – 0417 607 416
GU/neuro/Head & Neck/skin – 0436 387 664
Phase 1 – 0474 769 510

Breast | Gastrointestinal (GI) | Lung | Genitourinary (GU) | Gynaecology | Head & Neck | Skin | Neuro | PH 1

List of Principal Investigators at Monash Health:

Associate Professor Zee Wan Wong (ZW)
Associate Professor Surein Arulananda (SA)
Associate Professor Peter Briggs (PB)
Associate Professor Marion Harris (MH)
Associate Professor David Pook (DP)
Associate Professor Andrew Strickland (AS)
Associate Professor Michelle White (MW)
Dr Elizabeth Ahern (EA)
Dr Muhammad Alamgeer (MA)
Dr Adithya Balasubramaniam (AB)
Dr Amy Body (AB)
Dr Daphne Day (DD)
Dr Sophia Frentzas (SF)
Dr Harriet Herbison (HH)
Dr Joshua Hurwitz (JH)
Dr Gwo Yaw Ho (GH)
Dr Elizabeth Liow (EL)
Dr Amelia McCartney (AM)
Dr Kate Webber (KW)
Dr Michael Mond (MM)